MoonLake Immunotherapeutics (MLTX) Income towards Parent Company (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Income towards Parent Company of -$69.7 million for Q1 2026, down 71.87% year-over-year from -$247.8 million in Q1 2025, and down 10.61% quarter-over-quarter from -$63.0 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Income towards Parent Company (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$69.7 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 71.87% year-over-year to -$69.7 million; the TTM figure through Mar 2026 stood at -$259.5 million (down 75.52% YoY), while the FY2025 annual figure was -$230.3 million, down 89.96% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$69.7 million, down from -$63.0 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$7.9 million in Q4 2023, with the low at -$70.7 million in Q3 2025.
- The 5-year median for Income towards Parent Company is -$17.4 million (2022), against an average of -$31.2 million.
- Peak annual rise in Income towards Parent Company reached 69.3% in 2022, while the deepest fall reached 20715.22% in 2022.
- MoonLake Immunotherapeutics' Income towards Parent Company stood at -$16.5 million in 2022, then soared by 52.11% to -$7.9 million in 2023, then plunged by 488.23% to -$46.4 million in 2024, then sank by 35.83% to -$63.0 million in 2025, then fell by 10.61% to -$69.7 million in 2026.
- Business Quant data shows MLTX's Income towards Parent Company at -$69.7 million in Q1 2026, -$63.0 million in Q4 2025, and -$70.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.81 Mn |
| Mar 31, 2026 | -69.71 Mn |
| Dec 31, 2025 | -63.02 Mn |
| Sep 30, 2025 | -70.69 Mn |
| Jun 30, 2025 | -56.05 Mn |
| Mar 31, 2025 | -40.56 Mn |
| Dec 31, 2024 | -46.40 Mn |
| Sep 30, 2024 | -36.11 Mn |
| Jun 30, 2024 | -24.76 Mn |
| Mar 31, 2024 | -13.98 Mn |
| Dec 31, 2023 | -7.89 Mn |
| Sep 30, 2023 | -11.62 Mn |
| Jun 30, 2023 | -12.35 Mn |
| Mar 31, 2023 | -12.22 Mn |
| Dec 31, 2022 | -16.47 Mn |
| Sep 30, 2022 | -14.74 Mn |
| Jun 30, 2022 | -17.42 Mn |
| Mar 31, 2022 | -15.88 Mn |
| Dec 31, 2021 | -53.64 Mn |
| Sep 30, 2021 | -6.29 Mn |